PHARMACIE DES GRANDES TERRES : revenue, balance sheet and financial ratios

PHARMACIE DES GRANDES TERRES is a French company founded 10 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MARLY-LE-ROI (78160), this company of category PME shows in 2022 a revenue of 6.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DES GRANDES TERRES (SIREN 818225781)
Indicator 2025 2024 2023 2022 2019 2018 2017
Revenue N/C N/C N/C 6 417 803 € 5 732 699 € 5 324 325 € 6 439 368 €
Net income 482 783 € 382 526 € 370 329 € 410 240 € 193 156 € 234 308 € 78 298 €
EBITDA N/C N/C N/C 615 453 € 317 976 € 425 360 € 253 708 €
Net margin N/C N/C N/C 6.4% 3.4% 4.4% 1.2%

Revenue and income statement

In 2025, PHARMACIE DES GRANDES TERRES generates positive net income of 483 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 78 k€ -> 483 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

482 783 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 208%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 29%. The balance between equity and debt is satisfactory.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

207.841%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

29.309%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

14.8%

Solvency indicators evolution
PHARMACIE DES GRANDES TERRES

Sector positioning

Debt ratio
207.84 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average

In 2025, the debt ratio of PHARMACIE DES GRANDES TERRES (207.84) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
29.31% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average

In 2025, the financial autonomy of PHARMACIE DES GRANDES TERRES (29.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 175.61. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

175.614

Liquidity indicators evolution
PHARMACIE DES GRANDES TERRES

Sector positioning

Liquidity ratio
175.61 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average +20 pts over 3 years

In 2025, the liquidity ratio of PHARMACIE DES GRANDES TERRES (175.61) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DES GRANDES TERRES

Positioning of PHARMACIE DES GRANDES TERRES in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of PHARMACIE DES GRANDES TERRES is estimated at 7 669 065 € (range 5 204 263€ - 12 033 819€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
5204k€ 7669k€ 12033k€
7 669 065 € Range: 5 204 263€ - 12 033 819€
NAF 5 année 2025

Valuation method used

Net Income Multiple
482 783 € × 15.9x = 7 669 065 €
Range: 5 204 264€ - 12 033 820€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DES GRANDES TERRES with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE DES GRANDES TERRES

What is the revenue of PHARMACIE DES GRANDES TERRES ?

The revenue of PHARMACIE DES GRANDES TERRES in 2022 is 6.4 M€.

Is PHARMACIE DES GRANDES TERRES profitable?

Yes, PHARMACIE DES GRANDES TERRES generated a net profit of 483 k€ in 2025.

Where is the headquarters of PHARMACIE DES GRANDES TERRES ?

The headquarters of PHARMACIE DES GRANDES TERRES is located in MARLY-LE-ROI (78160), in the department Yvelines.

Where to find the tax return of PHARMACIE DES GRANDES TERRES ?

The tax return of PHARMACIE DES GRANDES TERRES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DES GRANDES TERRES operate?

PHARMACIE DES GRANDES TERRES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.